Cardiovascular risk prediction in HIV-infected patients: comparing the Framingham, atherosclerotic cardiovascular disease risk score (ASCVD), Systematic Coronary Risk Evaluation for the Netherlands (SCORE-NL) and Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) risk prediction models.
Maaike KrikkeR C HoogeveenA I M HoepelmanF L J VisserenJ E ArendsPublished in: HIV medicine (2015)
When using FHS-CVD and FHS-CHD, a higher overall CVD risk was attributed to the HIV-infected patients than when using the D:A:D, ASCVD and SCORE-NL models. This could have consequences regarding overtreatment, drug-related adverse events and drug-drug interactions.
Keyphrases
- hiv infected patients
- antiretroviral therapy
- hiv infected
- hiv positive
- cardiovascular disease
- human immunodeficiency virus
- hiv aids
- coronary artery disease
- coronary artery
- type diabetes
- electronic health record
- hepatitis c virus
- big data
- left ventricular
- metabolic syndrome
- hiv testing
- adverse drug
- artificial intelligence
- cardiovascular events